Associated Papers
CSF3R mutations and variants in myeloid neoplasms: associated phenotypes, co-mutations, and survival trends.
Bolarinwa A et al.
Haematologica, 2025
Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.
Barosi G et al.
Haematologica, 2025
Characterization of Genetic Landscape and Novel Inflammatory Biomarkers in Patients With Adult-Onset Still's Disease.
Topping J et al.
Arthritis & Rheumatology (hoboken, N.j.), 2025
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia.
Maffei R et al.
Annals of Hematology, 2025
Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations.
Gordon J et al.
Blood Cancer Journal, 2024
Germline CSF3R Variant in Chronic Myelomonocytic Leukemia: Linking Genetic Predisposition to Uncommon Hemorrhagic Symptoms.
Bochicchio MT et al.
International Journal of Molecular Sciences, 2023
Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity.
Molteni E et al.
Blood, 2023
The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease's phenotype.
Sobieralski P et al.
Frontiers in Oncology, 2023
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
González-López O et al.
Cancers, 2022
The Dawn of next generation DNA sequencing in myelodysplastic syndromes- experience from Pakistan.
Anwar N et al.
Bmc Genomics, 2021
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
Simonetti G et al.
Leukemia, 2021
Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies.
Trottier AM et al.
Blood Advances, 2020
Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia.
Canaani J et al.
Oncotarget, 2020
Pathogenic variants in KPTN gene identified by clinical whole-genome sequencing.
Thiffault I et al.
Cold Spring Harbor Molecular Case Studies, 2020
Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.
Carbonell D et al.
Cancers, 2019
Ultra-Sensitive CSF3R Deep Sequencing in Patients With Severe Congenital Neutropenia.
Klimiankou M et al.
Frontiers in Immunology, 2019
Clinical Correlates and Treatment Outcomes for Patients With Short Telomere Syndromes.
Mangaonkar AA et al.
Mayo Clinic Proceedings, 2018
Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer.
Feliubadaló L et al.
Scientific Reports, 2017
Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.
Magor GW et al.
The Journal of Molecular Diagnostics : Jmd, 2016
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Maxson JE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
Tefferi A et al.
Leukemia, 2014
Granulocyte colony-stimulating factor receptor mutations in myeloid malignancy.
Liongue C et al.
Frontiers in Oncology, 2014